Background: Pediatric Hodgkin’s lymphoma represents survival success story, however late toxicity remains as a big consideration issue. Patients & Methods: During the period July 2007 and December 2014, 694 pediatric classic Hodgkin’s lymphoma patients were treated according to risk-adapted protocol consisted of 4-8 ABDV chemotherapy courses and involved field radiotherapy (IFRT). Out of them 543 (78.2%) received IFRT with a dose of 19.8 Gy, while the other 151 (21.8%) did not receive radiotherapy for different reasons. Results: The 5-year overall (OS) and event-free survival (EFS) for the low risk patients were 99.7% and 92.6% respectively. These rates were 93.1% and 83.9% for the intermediate risk and 95.4% and 75.3% for the high risk respectively. The 5-year OS and EFS for those received IFRT were 98.0 % and 86.9 % respectively, while those who receive chemotherapy only were 92.9% and 77.8 % respectively (p˂0.001 for each). Radiotherapy could improve the 5-year EFS in the advanced (intermediate and high-risk) patients from 76.6 % to 79.4 % with marginal statistical significance (0.073). On the other hand, the OS improved from 94.5 % to 96.0 % though this difference did not reach the level of significance. Only one out of 318 low-risk patients died and 14 relapsed and could be salvaged. Only 25 low-risk patients did not receive IFRT and those did not show OS nor EFS differences from the 293 patients who received IFRT. Two patients developed acute myeloid leukemia & one developed thyroid cancer as second primary (0.43%). All of them received chemotherapy and IFRT. Conclusion: Involved field radiotherapy marginally improved the EFS in intermediate and high-risk pediatric Hodgkin’s lymphoma significantly, while its improvement in OS in such patients did not reach the significant statistical level. Low-risk patient needs prospective randomized trial to thoroughly investigate this issue.